The handle http://hdl.handle.net/1887/46717 holds various files of this Leiden University dissertation.

**Author:** Admiraal, R.  
**Title:** Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation - a delicate balance  
**Issue Date:** 2017-03-15
Chapter 8

Impact of alemtuzumab exposure on clinical outcomes of hematopoietic cell transplantation: are we overdosing children using I.V. dosing close to transplantation?

Rick Admiraal
Juliana M. Furtado Silva
Cornelia M. Jol-van der Zijde
Arjan C. Lankester
Jaap J. Boelens
Catherijne A.J. Knibbe
Geoff Hale
Annie Etuk
Melanie Wilson
Stuart Adams
Charlotte van Kesteren
Paul Veys
Robbert G.M. Bredius

Submitted
To the editor,

Alemtuzumab (Campath®, Genzyme, MA, USA) is used as serotherapy in hematopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure by in-vivo depletion of lymphocytes. Inclusion of alemtuzumab in the conditioning regimen significantly reduces the incidence of both acute and chronic GvHD<sup>1-3</sup>. Higher doses of alemtuzumab have been associated with delayed immune reconstitution (IR) by excessive lymphodepletion<sup>4-6</sup>. Poor IR could potentially lead to increased viral reactivations as well as less graft-versus-leukemia effect, thereby abrogating the beneficial effect on GvHD reduction.

A recent publication by Marsh and colleagues<sup>7</sup> in Blood described the impact of peri-transplant alemtuzumab concentrations on clinical outcomes. Low concentrations were associated with acute GvHD, while higher concentrations led to poor lymphocyte reconstitution and increased mixed chimerism.

We aim to evaluate these results in a larger cohort of children. We use a pharmacologically and methodologically stronger approach by calculating the alemtuzumab concentrations on the basis of a validated pharmacokinetic model<sup>8</sup>. This exactly estimates concentrations at the beginning of infusion of the graft rather than peri-transplant concentrations (±3 days) and eliminates some of the uncertainty incorporated in a single concentration measurement.

Children receiving their first HCT in the Leiden University Medical Center (Leiden, the Netherlands; LUMC) and Great Ormond Street Hospital (London, United Kingdom; GOSH) with alemtuzumab as part of the conditioning were included. Patients using other serotherapy drugs (anti-thymocyte globulin; ATG) within the same conditioning regimen were excluded. Data was collected after informed consent; ethical committee approval through trial numbers P01.028 (Leiden) and V0904 (London).

Alemtuzumab (Campath, Genzyme, USA) was dosed at 0.5 or 1 mg/kg (5 x 0.1-0.2 mg/kg/day) in most children. Details about the samples and alemtuzumab assay is available in the supplements. Conditioning regimens were given according to (inter)national protocols.

176 patients were included between January 2003 and July 2015 with a median age of 4.8 years (range 0.2-19 years; Table 1). Full description on the definitions and statistical approach can be found in the supplements. Fifty-four percent of patients received a cumulative dose of 1 mg/kg over 5 doses, 35% received a dose of <0.9 mg/kg. Median starting day was day -8 (-21 to -3). Immune deficiency was the most frequent indication for HCT. Median follow-up for surviving patients was 64 months (range 16.9-149).
Table 1. Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>London</th>
<th>Leiden</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients (n)</td>
<td>125</td>
<td>51</td>
<td>176</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>64</td>
<td>67</td>
<td>65</td>
</tr>
<tr>
<td>Age (years)</td>
<td>4.0 (0.4-15)</td>
<td>8.1 (0.2-19)</td>
<td>4.8 (0.2-19)</td>
</tr>
<tr>
<td>Cumulative dose (mg/kg) (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;0.9 mg/kg</td>
<td>36</td>
<td>29</td>
<td>35</td>
</tr>
<tr>
<td>0.9-1.1 mg/kg</td>
<td>50</td>
<td>65</td>
<td>54</td>
</tr>
<tr>
<td>&gt;1.1 mg/kg</td>
<td>14</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>Starting day alemtuzumab (days before transplantation)</td>
<td>8 (5-21)</td>
<td>6 (3-16)</td>
<td>8 (3-21)</td>
</tr>
<tr>
<td>Number of samples [n (mean per patient)]</td>
<td>309 (2.5)</td>
<td>557 (10.9)</td>
<td>866 (4.9)</td>
</tr>
<tr>
<td>Diagnosis (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancy</td>
<td>14</td>
<td>41</td>
<td>22</td>
</tr>
<tr>
<td>Immune deficiency</td>
<td>65</td>
<td>37</td>
<td>57</td>
</tr>
<tr>
<td>Bone marrow failure</td>
<td>15</td>
<td>20</td>
<td>16</td>
</tr>
<tr>
<td>Metabolic disease</td>
<td>5</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Benign hematology</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Stem cell source (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow</td>
<td>35</td>
<td>65</td>
<td>44</td>
</tr>
<tr>
<td>Peripheral blood stem cells</td>
<td>65</td>
<td>27</td>
<td>54</td>
</tr>
<tr>
<td>Cordblood</td>
<td>0</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Conditioning regimen (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduced intensity</td>
<td>45</td>
<td>63</td>
<td>50</td>
</tr>
<tr>
<td>Chemotherapy-based</td>
<td>50</td>
<td>31</td>
<td>45</td>
</tr>
<tr>
<td>TBI-based</td>
<td>5</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Follow-up surviving patients (months)</td>
<td>59 (17.3-130)</td>
<td>84 (16.9-149)</td>
<td>64 (16.9-149)</td>
</tr>
</tbody>
</table>

Shown as median (range) unless otherwise specified

A clear difference in $C_{\text{graft}}$ was observed compared to peri-transplant concentrations as reported by Marsh et al. In our cohort, 6 patients (3%) had a very low $C_{\text{graft}} < 0.155$ μg/mL, while $C_{\text{graft}}$ was very high (>4.36 μg/mL) in 38 patients (21%; Figure S1). In the Marsh report, of 18% and 8% had very low and very high concentrations, respectively. Other groups were comparable. Patients were analyzed in groups with a $C_{\text{graft}}$ < 1, 1-2, 2-3 and >3 μg/mL.

The incidence of grade 2-4 acute GvHD was impacted by $C_{\text{graft}}$. Patients with high $C_{\text{graft}}$ showed the lowest incidence, while the three groups with lower $C_{\text{graft}}$ performed worse (figure 1a). In multivariate analysis (MV), high $C_{\text{graft}}$ was associated with a lower incidence of acute GvHD in both grades 2-4 and 3-4 (hazard ratio [HR] 0.79, 95% confidence interval
Pharmacodynamics of Alemtuzumab in Children

[CI] 0.67-0.93, p=0.0046 and HR 0.58, 95% CI 0.38-0.87, p=0.0081, respectively; Table S1 and S2). No other multivariate predictors were identified. Chronic GvHD was not impacted by C graft (p=0.32 in MV analysis).

Mixed chimerism, defined as < 95% donor chimerism in 2 whole blood samples, did not differ between groups (figure 1b). In multivariate analysis, no significant impact of C graft on mixed chimerism could be identified (HR 1.03, 95% CI 0.93-1.13, p=0.60).

Overall survival was not impacted by C graft, both in univariate (fig 1c) and in multivariate analysis (HR 0.99, 95% CI 0.88-1.13, p=0.97). However, treatment after 2009 (median treat-
ment year in this cohort) was a multivariable predictor for improved survival (p=0.046, Table S2).

We also investigated viral reactivations of Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenovirus, defined as > 1000 viral copies/mL in 2 subsequent measurements. No difference in viral reactivations was found between groups of C_{graft} (HR 0.96, 95% CI 0.88-1.06, p=0.40; figure 3d).

Finally, the relation between C_{graft} and CD3+ T-cell counts was investigated. CD3+ immune reconstitution (IR) was defined as a CD3+ T-cell count >100 x 10^6/L in 2 samples before 100 days, as adapted from literature\textsuperscript{10}. While there were significant differences between groups of C_{graft}, the distribution of CD3+ kinetics not ordered in terms of C_{graft} (figure S2a). This is reflected in the multivariate analysis, where only a trend was found between C_{graft} and CD3+ IR (HR 1.14, 95% CI 0.99-1.31, p=0.060). The absolute CD3+ count at day 100 was not significantly different between groups (p=0.064; figure S2b).

These data suggest that high alemtuzumab concentrations during graft infusion may reduce the incidence of acute GvHD. Other outcome parameters including survival, mixed chimerism, viral reactivation and T-cell recovery are not impacted by alemtuzumab concentrations.

Compared to previous the study by Marsh et al\textsuperscript{7}, the alemtuzumab concentrations in this cohort are relatively high. Part of this difference may be due to differences in underlying disease and conditioning regimen. The dosing and route of administration are most likely larger contributors to the difference in alemtuzumab concentrations. The alemtuzumab dose used by Marsh (1mg/kg, or fixed dose of 33 mg [<10 kg] or 48 mg [>10kg]) is generally higher than was used in this cohort (0.5-1 mg/kg in most patients). However, the starting day was more proximal (i.e. closer to graft infusion) in the current study, and 66\% of patients received subcutaneous dosing in the Marsh-study\textsuperscript{7}. Subcutaneous dosing leads to a high first-pass metabolism, and results in a slower release, both reducing alemtuzumab concentrations in blood\textsuperscript{11}. Still, taking into account the higher C_{graft} in this cohort, the results are generally comparable. The most optimal therapeutic window has not been set convincingly.

From a pharmacological perspective, the most optimal dose for a drug shows the desired effects with minimal toxicity\textsuperscript{12}. For alemtuzumab, the desired effect is the prevention of GvHD and mixed chimerism, while toxicities include poor T-cell reconstitution and subsequent viral reactivations\textsuperscript{13}. In the current study, a moderate exposure-response effect can be identified for GvHD, not for mixed chimerism. Of note, stable mixed chimerism can be allowed in subgroups of patients. The C_{graft} however is not correlated to toxicity. It can be
Pharmacodynamics of Alemtuzumab in Children

concluded that a vast majority of patients had a supratherapeutic alemtuzumab exposure. This is in line with the final conclusion by Marsh, who reports the optimal $C_{\text{opt}}$ for alemtuzumab to be between 0.2-0.4 μg/mL.

Therapeutic drug monitoring (TDM) in combination with individualized dosing may be useful in assuring the most optimal alemtuzumab exposure. However, the long time window (±10 days) between the infusions and the graft infusion, combined with the narrow therapeutic window during graft infusion, may complicate this approach. Still, taking into account the very slow clearance and low lympholytic level of alemtuzumab, approaches to target exposure will be difficult. Anti-thymocyte globulin has a faster clearance and higher a lympholytic level, and therefore may be a more attractive therapeutic option to prevent GvHD and graft failure.

In conclusion, alemtuzumab concentrations at graft infusion after intravenous doses of 0.5-1 mg/kg starting 10-6 days before HCT results in supratherapeutic exposures. Dosing should be reduced, given earlier or administered subcutaneously.
REFERENCES


